A DNA binding indolocarbazole disaccharide derivative remains highly cytotoxic without inhibiting topoisomerase I

Anti-Cancer Drug Design

Volumn 14, Issue 5, 1999, Pages 433-442

  Qu, Xiaogang ^c   Chaires, Jonathan B ^c   Ohkubo, Mitsuru ^a   Yoshinari, Tomoko ^a   Nishimura, Susumu ^a   Bailly, Christian ^b  

^a TAIHO PHARMACEUTICAL CO LTD   (Japan)

^b INSERUM U 524   (France)

^c UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

Anti cancer drugs; Cytotoxicity; DNA binding; Indolocarbazole; Rebeccamycin; Topoisomerase I

Indexed keywords

6 FORMYLAMINO 12,13 DIHYDRO 1,11 DIHYDROXY 5H INDOLO[2,3 A][PYRROLO[3,4 C]CARBAZOLE 5,7(6H) DIONE 13 GLUCOSIDE; CARBAZOLE DERIVATIVE; DNA; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); GLUCOSE; MALTOSE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DNA CLEAVAGE; DNA FOOTPRINTING; DNA SEQUENCE; DRUG CYTOTOXICITY; DRUG DNA BINDING; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; FLUORESCENCE ANALYSIS; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; CARBAZOLES; CATTLE; DNA; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; GLUCOSIDES; HUMANS; TUMOR CELLS, CULTURED;

ANIMALIA; MURINAE;

EID: 0033497816     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Anizon F., Belin L., Moreau P., Sancelme M., Voldoire A., Prudhomme M., Ollier M., Sevère D., Riou J.F., Bailly C., Fabro D., Meyer T. (1997) Syntheses and biological activity (topoisomerases inhibition, antitumoral and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group. Journal of Medicinal Chemistry, 40, 3456.
2. Anizon F., Moreau P., Sancelme M., Voldoire A., Prudhomme M., Ollier M., Sevère D., Riou J.F., Bailly C., Fabro D., Meyer T., Aubertin A.M. (1998) Synthesis, biochemical and biological evaluation of staurosporine analogs from the microbial metabolite rebeccamycin. Bioorganic and Medicinal Chemistry, 66, 1597.
3. Arakawa H., Iguchi T., Yoshinari T., Kojiri K., Suda H., Okura A. (1993) ED-110, a novel indolocarbazole, prevents the growth of experimental tumors in mice. Japanese Journal of Cancer Research, 84, 574.
4. Arakawa H., Iguchi T., Morita M., Yoshinari T., Kojiri K., Suda H., Okura A., Nishimura S. (1995) Novel indolocarbazole compound 6-N-formylamino-12,13-dihydro-1, 11-dihydroxy-13-(β-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo-[3,4-c] carbazole-5,7-(6H)-dione (NB-506): its potent antitumor activities in mice. Cancer Research, 55, 1316.
5. Arcamone F.A., Animati F., Berettoni M., Bigioni M., Capranico G., Cesazza A.M., Caserini C., Cipollone A., De Casare M., Franciotti M., Lombradi P., Madami A., Manzini S., Monteagudo E., Polizzi D., Pratesi G., Righetti S.C., Salvatore C., Supino R., Zunino F. (1997) Doxorubin disaccharide analogue: apoptosis-related improvement of efficacy in vivo. Journal of the National Cancer Institute, 89, 1217.
6. Arcamone F.A., Animati F., Bigioni M., Capranico G., Caserini C., Cipollone A., De Cesare M., Ettore A., Guano F., Manzini S., Monteagudo E., Pratesi G., Salvatore C., Supino R., Zunino F. (1999) Configurational requirements of the sugar moiety for the pharmacological activity of anthracycline disaccharides. Biochemical Pharmacology, 57, 1133.
7. Bailly C., Waring M.J. (1995) Comparison of different footprinting methodologies for detecting binding sites for a small ligand on DNA. Journal of Biomolecular Structure and Dynamics, 12, 869.
8. Bailly C., Riou J.F., Colson P., Houssier C., Rodrigues-Pereira E., Prudhomme M. (1997) DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin. Biochemistry, 36, 3917.
9. Bailly C., Colson P., Houssier C., Rodrigues-Pereira E., Prudhomme M., Waring M.J. (1998) Recognition of specific sequences in DNA by a topoisomerase I inhibitor derived from the antitumor drug rebeccamycin. Molecular Pharmacology, 53, 77.
10. Bailly C., Dassonneville L., Colson P., Houssier C., Fukasawa K., Nishimura S., Yoshinari T. (1999a) Intercalation into DNA is not required for inhibition of topoisomerase I by indolocarbazole antitumor agents. Cancer Research, 59, 2853.
11. Bailly C., Qu X., Graves D.E., Prudhomme M., Chaires J.B. (1999b) Calories from carbohydrates. Energetic contribution of the carbohydrate moiety of rebeccamycin to DNA binding and the effect of its orientation on topoisomerase I inhibition. Chemistry & Biology, 6, 277.
12. Bailly C., Qu X., Anizon F., Prudhomme M., Riou J.F., Chaires J.B. (1999c) Enhanced binding to DNA and topoisomerase I inhibition by an analog of the antitumor antibiotic rebeccamycin containing an amino-sugar residue. Molecular Pharmacology, 55, 377.
13. Bailly C., Qu X., Chaires J.B., Colson P., Houssier C., Ohkubo M., Nishimura S., Yoshinari T. (1999d) Substitution at the F-ring N-imide of the indolocarbazole antitumor drug NB-506 increases the cytotoxicity, DNA binding and topoisomerase I inhibition activities. Journal of Medicinal Chemistry, 42, 2927.
14. Chaires J.B. (1996) Dissecting the free energy of drug binding to DNA. Anti-Cancer Drug Design, 11, 569.
15. Chaires J.B., Priebe W., Graves D.E., Burke T.G. (1993) Dissection of the free energy of anthracycline antibiotic binding to DNA: electrostatic contributions. Journal of the American Chemical Society, 115, 5360.
16. Crow R.T., Crothers D.M. (1994) Inhibition of topoisomerase I by anthracycline antibiotics: evidence for general inhibition of topoisomerase I by DNA binding agents. Journal of Medicinal Chemistry, 37, 3191.
17. Friedman R.A., Manning G.S. (1984) Polyelectrolyte effects on site-binding equilibria with application to the intercalation of drugs into DNA. Biopolymers, 23, 2671.
18. Fukada M. (1985) Action of camptothecin and its derivatives on deoxyribonucleic acid. Biochemical Pharmacology, 34, 1225.
19. Fukasawa K., Komatani H., Hara Y., Suda H., Okura A., Nishimura S., Yoshinari T. (1998) Sequence-selective cleavage by a topoisomerase I poison, NB-506. International Journal of Cancer, 75, 145.
20. Guano F., Pourquier P., Tinelli S., Binaschi M., Bigioni M., Animati F., Manzini S., Zunino F., Kohlhagen G., Pommier Y., Capranico G. (1999) Topoisomerase poisoning activity of novel disaccharide anthracyclines. Molecular Pharmacology, 67, 77.
21. Kanzawa F., Nishio K., Kubota N., Saijo N. (1995) Antitumor activities of a new indolocarbazole substance, NB-506, and establishment of NB-506-resistant cell lines, SBC-3/NB. Cancer Research, 55, 2806.
22. Kojiri K., Kondo H., Yoshinari T., Arakawa H., Nakajima S., Satoh F., Kawamura K., Okura A., Suda H., Okanishi M. (1991) A new antitumor substance BE-13793C, produced by a streptomycete. Taxonomy, fermentation, isolation, structure determination and biological activity. Journal of Antibiotics, 44, 723.
23. Larsen A.K., Grondard L., Couprie J., Desoize B., Comoe L., Jardillier J.C., Riou J.F. (1993) The antileukemic alkaloid fagaronine is an inhibitor of DNA topoisomerases I and II. Biochemical Pharmacology, 46, 1403.
24. Moreau P., Anizon F., Sancelme M., Prudhomme M., Bailly C., Carrasco C., Ollier M., Sevère D., Riou J.F., Fabbro D., Meyer T., Aubertin A.M. (1998) Syntheses and biological evaluation of indolocarbazoles, analogues of rebeccamycin, modified at the imide heterocycle. Journal of Medicinal Chemistry, 41, 1631.
25. Moreau P., Anizon F., Sancelme M., Prudhomme M., Sevère D., Riou J.F., Goossens J.F., Hénichart J.P., Bailly C., Labourier E., Tazi J., Fabbro D., Meyer T., Aubertin A.M. (1999) Synthesis, mode of action and biological activities of rebeccamycin bromo-derivatives. Journal of Medicinal Chemistry, 42, 1816.
26. Ohe Y., Tanigawara Y., Fujii H., Ohtsu T., Wakita H., Igarashi T., Minami H., Eguchi K., Shinkai T., Tamura T., Kunotoh H., Saijo N., Okada K., Ogino H., Sasaki Y. (1997) Phase I and pharmacology study of 5-day infusion of NB-506. Proceedings of the American Cancer Society, 16, 199a.
27. Ohkubo M., Kawamoto H., Ohno T., Nakano M., Morishima H. (1997) Synthesis of NB-506, a new anticancer agent. Tetrahedron, 53, 585.
28. Ohkubo M., Kojiri K., Kondo H., Tanaka S., Kawamoto H., Nishimura T., Nishimura I., Yoshinari T., Arakawa H., Suda H., Morishima H., Nishimura S. (1999) Synthesis and biological activities of topoisomerase I inhibitors, 6-N-amino analogues of NB-506. Bioorganic and Medicinal Chemistry Letters, 9, 1219.
29. Pratesi G., De Cesare M., Caserini C., Perego P., Dal Bo L., Polizzi D., Supino R., Bigioni M., Manzini S., Iafrate E., Salvatore C., Casazza A., Arcamone F., Zunino F. (1998) Improved efficacy and enlarged spectrum of activity of a novel anthracycline disaccharide analogue of doxorubicin against human tumor xenografts. Clinical Cancer Research, 4, 2833.
30. Record M.T., Anderson C.F., Lohman T.M. (1978) Thermodynamic analysis of ion effects on the binding and conformational equilibria of proteins and nucleic acids: the role of ion association or release, screening, and ion effects on water activity. Quarterly Review of Biophysics, 11, 103.
31. Rodrigues-Pereira E., Belin L., Sancelme M., Prudhomme M., Ollier M., Rapp M., Servère D., Riou J.F., Fabbro D. (1996) Structure-activity relationships in a series of substituted indolocarbazoles: topoisomerase I and protein kinase C inhibition and antitumoral and antimicrobial properties. Journal of Medicinal Chemistry, 39, 4471.
32. Rubinstein L.V., Shoemaker R.H., Paull K.D., Simon R.M., Tosini S., Skehan P., Scudiero D.A., Monks A., Boyd M.R. (1990) Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium asay versus a protein assay against diverse panel of human tumor cell lines. Journal of the National Cancer Institute, 82, 1113.
33. Saijo N. (1998) New chemotherapeutic agents for the treatment of non-small cell lung cancer. Chest, 113, 17S.
34. Skehan P., Storeng R., Scudiero D., Monks A., MaMahon J., Vistica D., Warren J.T., Bokesch S., Boyd M.R. (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. Journal of the National Cancer Institute, 82, 1107.
35. Tanaka S., Ohkubo M., Kojiri K., Suda H., Yamada A., Uemura D. (1992) A new indolopyrrolocarbazole antitumor substance, ED-110, a derivative of BE-13793C. Journal of Antibiotics, 45, 1797.
36. Vanhoefer U., Voigt W., Hilger R.A., Yin M.-B., Harstrick A., Seeber S., Rustum Y.M. (1997) Cellular determinants of resistance to indolocarbazole analogue NB-506. A novel potent topoisomerase I inhibitor, in multidrug-resistant human tumor cells. Oncology Research, 9, 485.
37. Xie G., Gupta R., Atchison K., Lown J.W. (1996) Bisindolyl-maleimides linked to DNA minor groove binding lexitropsins: synthesis, inhibitory activity against topoisomerase I, and biological evaluation. Journal of Medicinal Chemistry, 39, 1049.
38. Yamashita Y., Fujii N., Murakata C., Ashizawa T., Okabe M., Nakano H. (1992) Induction of mammalian DNA topoisomerase I mediated DNA cleavage by antitumor indolocarbazole derivatives. Biochemistry, 31, 12069.
39. Yoshinari T., Yamada A., Uemura D., Nomura K., Arakawa H., Kojiri K., Yoshida E., Suda H., Okura A. (1993) Induction of topoisomerase I-mediated DNA cleavage by a new indolocarbazole, ED-110. Cancer Research, 53, 490.
40. Yoshinari T., Matsumoto M., Arakawa H., Okada H., Noguchi K., Suda H., Okura A., Nishimura S. (1995) Novel antitumor indolocarbazole compound 6-N-formyl-amino-12,13-dihydro-1,11-dihydroxy-13-(β-D-glucopyranosyl)-5H- indolo[2, 3-a]pyrrolo-[3, 4-c]carbazole-5,7-(6H)-dione (NB-506): induction of topoisomerase I-mediated DNA cleavage and mechanisms of cell line-selective cytotoxicity. Cancer Research, 55, 1310.